Adage Capital Partners Gp, L.L.C. Xenon Pharmaceuticals Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,914,749 shares of XENE stock, worth $60 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
1,914,749
Previous 1,863,473
2.75%
Holding current value
$60 Million
Previous $73 Million
12.06%
% of portfolio
0.12%
Previous 0.13%
Shares
23 transactions
Others Institutions Holding XENE
# of Institutions
220Shares Held
70.2MCall Options Held
444KPut Options Held
207K-
Avoro Capital Advisors LLC New York, NY5.74MShares$180 Million3.12% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.58MShares$144 Million1.68% of portfolio
-
Wellington Management Group LLP Boston, MA3.79MShares$119 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.33MShares$104 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.09MShares$96.8 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $1.95B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...